- All
- State-of-the-art Session
- Postgraduate Course
- Concurrent Session
- Oral Presentation
- Young Investigator Forum
- Special Session - Pediatrics Issue
- Satellite Symposium
- All
- 2022-09-16 [Friday]
- 2022-09-17 [Saturday]
- 2022-09-18 [Sunday]
- All
- Meeting Room 1
- Meeting Room 2
- Meeting Room 3
2022-09-18 Sunday
Meeting Room 1 (UTC+8) 2022-09-18 Local Time
| Beijing Time (UTC+8) | Local Time | Presentation Topic | Speaker | Affiliation / Organization |
|---|---|---|---|---|
| 08:30-09:00 | 08:30-09:00 |
Dynamic bioenergetics of sepsis in ACLF |
Shiv Kumar Sarin | Institute Of Liver And Biliary Sciences |
| 09:00-09:30 | 09:00-09:30 |
Mesenchymal Stem Cell Therapy for ACLF and DLC Patients |
Fusheng Wang | The Fifth Medical Center of PLA General Hospital |
| 09:30-11:00 | 09:30-11:00 |
Recent advances and pharmacological treatments in severe alcohol associated hepatitis |
Gyongyi SZABO | Beth Israel Deaconess Medical Center & Harvard Medical School |
| Beijing Time (UTC+8) | Local Time | Presentation Topic | Speaker | Affiliation / Organization |
|---|---|---|---|---|
| 10:00-10:20 | 10:00-10:20 |
Inflammation in NASH: regulators and therapeutic targets |
Bin GAO | Laboratory of Liver Diseases, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health |
| 10:20-10:40 | 10:20-10:40 |
Diagnosis and assessment of cirrhosis in non-alcoholic fatty liver disease |
Vincent Wong | The Chinese University of Hong Kong |
| 10:40-11:00 | 10:40-11:00 |
Leveraging fatty acid oxidation in skeletal muscle for the management of non-alcoholic fatty liver disease |
David E. COHEN | Weill Cornell Medical Center, New York |
| 11:00-11:20 | 11:00-11:20 |
Prevalence and impact of co-existing NAFLD in patients with HBV infection |
Chun-Jen LIU | Hepatitis Research Center, National Taiwan University Hospital |
| 11:20-11:30 | 11:20-11:30 |
Panel Discussion |
||
| Beijing Time (UTC+8) | Local Time | Presentation Topic | Speaker | Affiliation / Organization |
|---|---|---|---|---|
| 11:45-11:57 | 11:45-11:57 |
Soluble ST2 Serum Concentration Predicts Efficacy of Artificial liver support system in Acute-on-chronic liver failure. |
Rui QIANG | Infectious disease hospital affiliated to Suzhou University |
| 11:57-12:09 | 11:57-12:09 |
Upregulation of microRNA-125b-5p alleviates acute liver failure through regulating Keap1/Nrf2/HO-1 pathway |
Yachao TAO | West China Hospital of Sichuan University |
| 12:09-12:21 | 12:09-12:21 |
Decreased vitamin D-binding protein level portends poor outcome in acute-on-chronic liver failure caused by hepatitis B virus |
Daxian Wu | the First Affiliated Hospital, Nanchang University |
| 12:21-12:33 | 12:21-12:33 |
Galectin-3 critically mediates the hepatoprotection conferred by M2-like macrophages in acute-on-chronic liver failure by inhibiting pyroptosis but not necroptosis signalling |
Wang Lu | Beijing You An Hospital, Capital Medical University |
| 12:33-12:45 | 12:33-12:45 |
Contrast-free ultrasensitive ultrasound imaging for in-vivo quantitative evaluation of hepatic microcirculation in cirrhotic rats |
Wei ZHANG | The third affiliated hospital of Sun Yat-sen University |
| 12:45-12:57 | 12:45-12:57 |
Monocyte subsets predicts outcome of hepatitis B virus related Acute-on-Chronic Liver Failure patients |
Hongmin WANG | Senior Department of Hepatology, the Fifth Medical Center of PLA General Hospital |
| 12:57-13:09 | 12:57-13:09 |
Prediction of prognosis of hepatitis B virus-related acute-on-chronic liver failure by LEAP-HBV model based on whole liver volume |
Qijuan ZANG | First Affiliated Teaching Hospital, School of Medicine (SOM), Xi'an Jiaotong University |
| Beijing Time (UTC+8) | Local Time | Presentation Topic | Speaker | Affiliation / Organization |
|---|---|---|---|---|
| 13:45-14:05 | 13:45-14:05 |
Viral infection, inflammation and lipid metabolism |
Xiaojing WANG | Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology |
| 14:05-14:25 | 14:05-14:25 |
From NAFLD to MAFLD |
Jiangao Fan | Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine |
| 14:25-14:45 | 14:25-14:45 |
MAFLD and liver cancer |
Jacob George | University of Sydney |
| 14:45-15:05 | 14:45-15:05 |
MAFLD and extrahepatic manifestation |
Lai WEI | Beijing Tsinghua Changgung Hospital |
| 15:05-15:15 | 15:05-15:15 |
Panel Discussion |
||
| Beijing Time (UTC+8) | Local Time | Presentation Topic | Speaker | Affiliation / Organization |
|---|---|---|---|---|
| 15:30-16:00 | 15:30-16:00 |
Biotherapy for liver diseases |
Yuquan WEI | West China Hospital of Sichuan University |
| 16:00-16:30 | 16:00-16:30 |
Optimal management in the era of evolution of the treatment for HCC |
Kwang-Hyub HAN | Yonsei University College of Medicine |
| 16:30-17:00 | 16:30-17:00 |
Ex-vivo Liver Resection and Autotransplantation(ELRA): benign (parasitic) tumors |
Jiahong Dong | Beijing Tsinghua Chang Gung hospital |
| Beijing Time (UTC+8) | Local Time | Presentation Topic | Speaker | Affiliation / Organization |
|---|---|---|---|---|
| 17:00-17:20 | 17:00-17:20 |
Evidence to support changing the treatment thresholds in CHB |
Patrick T.F. KENNEDY | Barts Liver Centre，Blizard Institute，Barts and The London School of Medicine and Dentistry |
| 17:20-17:40 | 17:20-17:40 |
Boosting viral-specific immune therapy by mimogen for cure of chronic hepatitis B |
Yuzhang WU | Army Medical University, Chongqing |
| 17:40-18:00 | 17:40-18:00 |
Liver injury in patients with COVID-19 |
Xinxin ZHANG | Ruijin Hospital, Shanghai Jiao Tong University School of Medicine |
| 18:00-18:20 | 18:00-18:20 |
Pay more attention to HEV and HBV superinfection clinically |
Xiaoguang DOU | Shengjing Hospital of China Medical University |
| 18:20-18:30 | 18:20-18:30 |
Panel Discussion |
||